Conflict of Interest: None
Intra-Arterial Milrinone for Reversible Cerebral Vasoconstriction Syndrome
Version of Record online: 21 JUL 2008
© 2008 the Authors. Journal compilation © 2008 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 49, Issue 1, pages 142–145, January 2009
How to Cite
Bouchard, M., Verreault, S., Gariépy, J.-L. and Dupré, N. (2009), Intra-Arterial Milrinone for Reversible Cerebral Vasoconstriction Syndrome. Headache: The Journal of Head and Face Pain, 49: 142–145. doi: 10.1111/j.1526-4610.2008.01211.x
- Issue online: 5 JAN 2009
- Version of Record online: 21 JUL 2008
- Accepted for publication May 21, 2008.
Reversible cerebral vasoconstriction syndrome (RCVS) usually presents with recurrent thunderclap headaches and is characterized by multifocal and reversible vasoconstriction of cerebral arteries that can sometimes evolve to severe cerebral ischemia and stroke. We describe the case of a patient who presented with a clinically typical RCVS and developed focal neurological symptoms and signs despite oral treatment with calcium channel blockers. Within hours of neurological deterioration, she was treated with intra-arterial milrinone, a phosphodiesterase inhibitor, which resulted in a rapid and sustained neurological improvement.